08:04 AM EDT, 09/17/2024 (MT Newswires) -- Cullinan Therapeutics ( CGEM ) said Tuesday it has secured the Human Research Ethics Committee's approval in Australia to begin a global phase 1 clinical study to assess CLN-978 as a systemic lupus erythematosus treatment.

The study, which is meant to evaluate the safety, pharmacokinetics, and preliminary clinical activity of the experimental therapy, will be carried out across multiple locations in Australia and other parts of the world, the company said.